EURIDIS/ADONIS: After 1 year, 62.3% of patients free from symptomatic recurrence (vs 54% for placebo) 1 This analysis was a preplanned assessment of the primary endpoint data that excluded patients who discontinued treatment or experienced recurrence of atrial fibrillation before reaching 5 days of study drug exposure. 1 Symptomatic AFib recurrence included 1 or more of the following symptom(s ....